Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SAN RAMON, Calif., Oct. 26, 2016 -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that the Company will report its third quarter 2016 financial results and provide a corporate update on Wednesday, November 9, 2016 after the close of the financial markets. The company will host a conference call following the announcement at 2:00 pm P.T./5:00 pm E.T. to discuss the financial and business results.
The live webcast will include slides that can be accessed on the Company's website under the Investors section/Events and Presentations: http://investors.galenabiopharma.com/events.cfm. The conference call can be accessed by dialing (844) 825-4413 toll-free in the U.S., or (973) 638-3403 for participants outside the U.S. The Conference ID number is: 7629100. The archived webcast replay will be available on the Company's website for one year.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, and novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (503) 405-8258 [email protected]
